Class of 2024
For pioneering innovative structure-based chemical biology approaches to designing and developing protein inhibitors and degraders that have transformed the future of cancer therapeutics, and for spearheading novel combinatorial chemistry and genomic approaches that have resulted in the development of several cancer therapies, including ceritinib, asciminib, and osimertinib.
*Full-length biography pending